Psiquiatría
Servicio
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (8)
2022
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
2015
-
Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors
Annals of General Psychiatry, Vol. 14, Núm. 1
-
Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice
Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340
-
Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms
International Clinical Psychopharmacology, Vol. 30, Núm. 5, pp. 265-271
2013
-
A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain
Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174
-
Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain
Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996
2012
-
Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study
Clinical Practice and Epidemiology in Mental Health, Vol. 8, pp. 158-168
-
Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain
ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168